Seite - (000311) - in Biomedical Chemistry: Current Trends and Developments

Compound Sequence Ki ± SEM (nM) 1 (SP1–7) H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH 1.6 ± 0.1 2 (EM-2) H-Tyr-Pro-Phe-Phe-NH2 8.7 ± 0.1 Alanine-substituted SP1–7 3 H-Ala-Pro-Lys-Pro-Gln-Gln-Phe-OH 12.3 ± 0.4 4 H-Arg-Ala-Lys-Pro-Gln-Gln-Phe-OH 1.7 ± 0.1 5 H-Arg-Pro-Ala-Pro-Gln-Gln-Phe-OH 2.8 ± 0.1 6 H-Arg-Pro-Lys-Ala-Gln-Gln-Phe-OH 2.8 ± 0.1 7 H-Arg-Pro-Lys-Pro-Ala-Gln-Phe-OH 78.6 ± 5.1 8 H-Arg-Pro-Lys-Pro-Gln-Ala-Phe-OH 365 ± 3 9 H-Arg-Pro-Lys-Pro-Gln-Gln-Ala-OH > 10 000 Alanine-substituted EM-2 10 H-Ala-Pro-Phe-Phe-NH2 11.5 ± 0.1 11 H-Tyr-Ala-Phe-Phe-NH2 10.2 ± 0.3 12 H-Tyr-Pro-Ala-Phe-NH2 9.4 ± 0.1 13 H-Tyr-Pro-Phe-Ala-NH2 1460 ± 15 Terminally Modified SP1–7 and EM-2 14 Ac-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH 7.1 ± 0.0